Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Reaffirmed as Buy by HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $44.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 66.95% from the company’s current price.

A number of other research analysts have also weighed in on the stock. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Zenas BioPharma in a research note on Wednesday, September 30th. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Morgan Stanley boosted their target price on shares of Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. Citigroup upped their target price on shares of Zenas BioPharma from $41.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, September 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zenas BioPharma in a research report on Tuesday, October 6th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Zenas BioPharma has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Zenas BioPharma Stock Down 0.2%

Shares of NASDAQ ZBIO traded down $0.05 during midday trading on Tuesday, hitting $26.36. 80,170 shares of the stock traded hands, compared to its average volume of 811,894. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. Zenas BioPharma has a one year low of $13.50 and a one year high of $44.60. The business has a 50 day moving average price of $30.71 and a two-hundred day moving average price of $25.37. The company has a market cap of $1.72 billion, a PE ratio of -2.93 and a beta of -0.90.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Thursday, August 13th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The company had revenue of $1.00 million during the quarter, compared to the consensus estimate of $15.00 million. On average, equities analysts predict that Zenas BioPharma will post -5.81 EPS for the current year.

Institutional Investors Weigh In On Zenas BioPharma

A number of institutional investors and hedge funds have recently bought and sold shares of ZBIO. Quantbot Technologies LP bought a new position in Zenas BioPharma during the 2nd quarter valued at $49,000. Jupiter Topco LLC purchased a new position in Zenas BioPharma during the 2nd quarter worth $201,000. The Manufacturers Life Insurance Company bought a new stake in shares of Zenas BioPharma in the 2nd quarter worth $204,000. Sei Investments Co. bought a new stake in shares of Zenas BioPharma in the 1st quarter worth $242,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Zenas BioPharma in the second quarter valued at about $329,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.